Healthy Volunteers
Conditions
Interventions
investigational material(s)
Generic name etc : TAK-123
INN of investigational material : -
Therapeutic category code : 399 Agents affecting metabolism, n.e.c.
Dosage and Administration for Investigati
Sponsors
Takeda Pharmaceutical Company Limited
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. The participant is capable of understanding and complying with protocol requirements in the opinion of the investigator or sub-investigator. 2. The participant signs and dates a written informed consent form prior to the initiation of any study procedures. 3. The participant is a Japanese healthy adult male. 4. The participant is aged 20 to 45 years inclusive at the time of informed consent. 5. The participant weighs at least 50.0 kg, and has a body mass index (BMI) between 18.5 and 25.0 kg/m^2, inclusive, at Screening. 6. The participant is sterile, vasectomized or agrees to use an appropriate method of contraception throughout the treatment period.
Exclusion criteria
Exclusion criteria: 1. The participant has received any investigational drugs within 90 days before screening for this study (including the cases that at least 5 times the elimination half-lives of any investigational drugs have not yet passed). 2. The participant previously received TAK-123, its ingredients, or related compound before participation in this study except for the cases where benzoic acid is ingested as a food additive. 3. The participant is an employee of the study site, or immediate family member, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or who may be coerced to provide consent. 4. The participants have previous or current history of diseases that may affect the participation in this study or study results, including uncontrolled, clinically relevant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, endocrine, hematologic, immune, skin disease or psychiatric disorder. 5. The participant has a history of multiple episodes or severe allergies (example, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerance to prescription drugs, over-the-counter (OTC) drugs or foods. 6. The participant has had an anaphylactic reaction to active ingredients or additives of TAK-123, ondansetron or additives of ondansetron, or salicylic acid associated with the intravenous administration of TAK-123. 7. The participant has a positive urine drug test at the time of screening. 8. The participant has a history of drug abuse (defined as any illicit drug use) or has a history of alcohol dependence within 2 years before the start of screening or is unwilling to agree to abstain from alcohol and drugs throughout the study. 9. The participant consumes 6 or more servings of caffeinated beverages (containing about 720 mg of caffeine or more) such as coffee, tea, cola, or energy drinks per day. 10. The participant is a smoker who smoked cigarettes or used nicotine-containing products (such as nicotine patch) within 6 months before the study drug administration. 11. The participant has a history of cancer. 12. The participant has a positive test result for any of the following at the time of screening: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, serological test for syphilis. 13. The participant has poor peripheral venous access. 14. The participant has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to the start of the study drug administration. 15. The participant has undergone whole blood collection of at least 800 mL in total within 52 weeks (364 days) prior to the start of the study drug administration. 16. The participant has undergone blood component collection within 2 weeks (14 days) prior to the start of the study drug administration. 17. The participant has any clinically relevant abnormality in vital signs or 12-lead electrocardiogram (ECG) at screening or predose of Day 1. 18. The participant has abnormal laboratory test values at screening indicating clinically relevant underlying disease, or showing alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 x upper limit of normal (ULN). 19. The participant has been on an abnormal diet (example, excessive drinking and eating or starvation condition) during the fo
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pharmacokinetics Cmax: Maximum Observed Plasma Concentration for Phenylacetate, Benzoate, and Their Metabolites (Phenylacetylglutamine and Hippurate) Time Frame: Day 1 pre- infusion and at 0.25, 0.75, 1.5, 2.5, 4.5, 6.5, 8.5, 10.5, 12.5, 16.5, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29.5, 30.5, 32.5 and 48 hours post- infusion pharmacokinetics AUClast: Area under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Phenylacetate, Benzoate, and Their Metabolites (Phenylacetylglutamine and Hippurate) Time Frame: Day 1 pre- infusion and 0.25, 0.75, 1.5, 2.5, 4.5, 6.5, 8.5, 10.5, 12.5, 16.5, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29.5, 30.5, 32.5 and 48 hours post- infusion pharmacokinetics AUC(infinity): Area under the Plasma Concentration-time Curve from Time 0 to Infinity for Phenylacetate, Benzoate, and Their Metabolites (Phenylacetylglutamine and Hippurate) Time Frame: Day 1 pre- infusion and 0.25, 0.75, 1.5, 2.5, 4.5, 6.5, 8.5, 10.5, 12.5, 16.5, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29.5, 30.5, 32.5 and 48 hours post- infusion | — |
Secondary
| Measure | Time frame |
|---|---|
| safety Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) Time Frame: Day 1 up to Day 8 | — |
Countries
Japan
Outcome results
None listed